Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Cash & Current Investments (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Cash & Current Investments data on record, last reported at $98.6 million in Q3 2025.

  • For Q3 2025, Cash & Current Investments rose 15.92% year-over-year to $98.6 million; the TTM value through Sep 2025 reached $98.6 million, up 15.92%, while the annual FY2024 figure was $151.5 million, 283.7% up from the prior year.
  • Cash & Current Investments reached $98.6 million in Q3 2025 per CAPR's latest filing, down from $122.8 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $151.5 million in Q4 2024 and bottomed at $28.5 million in Q3 2023.
  • Average Cash & Current Investments over 5 years is $61.9 million, with a median of $41.9 million recorded in 2021.
  • Peak YoY movement for Cash & Current Investments: plummeted 38.81% in 2023, then surged 316.81% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $34.9 million in 2021, then increased by 18.74% to $41.4 million in 2022, then fell by 4.67% to $39.5 million in 2023, then soared by 283.7% to $151.5 million in 2024, then crashed by 34.95% to $98.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $98.6 million in Q3 2025, $122.8 million in Q2 2025, and $144.8 million in Q1 2025.